| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_df4441af14454b36a004abf14d184e20 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-569
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-94 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2809
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-303
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2896
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18 |
| filingDate |
2016-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6b5e19d2325d623cf6d2a2863a2a7b46 |
| publicationDate |
2017-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2017152316-A1 |
| titleOfInvention |
Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells |
| abstract |
A targeted T-cell engaging agent for treating a condition characterized by the presence of unwanted cells includes (a) a targeting moiety that is capable of targeting the unwanted cells; (b) a first T-cell engaging domain capable of T-cell engaging activity when binding a second T-cell engaging domain, wherein the second T-cell engaging domain is not part of the agent; (c) at least one inert binding partner capable of binding to the first T-cell engaging domain such that the first T-cell engaging domain does not bind to the second T-cell engaging domain unless the inert binding partner is removed; and (d) at least one cleavage site separating the first T-cell engaging domain and the inert binding partner, wherein the cleavage site is: (i) cleaved by an enzyme expressed by the unwanted cells; (ii) cleaved through a pH-sensitive cleavage reaction inside the unwanted cell; (iii) cleaved by a complement-dependent cleavage reaction; or (iv) cleaved by a protease that is colocalized to the unwanted cell by a targeting moiety that is the same or different from the targeting moiety in the agent. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10815311-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11623958-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11607453-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11136403-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10844134-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10849973-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10544221-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11453716-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10543271-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11535668-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11560408-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10954311-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018204717-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10927180-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10730954-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11180563-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11285203-B2 |
| priorityDate |
2015-11-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |